Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: A new polysaccharide platform constructs self-adjuvant nanovaccines to enhance immune responses

Fig. 3

Immune responses induced by PRBS-based nanovaccines. a Schematic diagram of immunization procedure. Each mouse received three immunizations with an interval of two weeks. After one week of the final immunization, mice were sacrificed for the immunological assay. bThe 50% inhibitory concentration (IC50) of anti-SARS-CoV-2 neutralizating antibodies induced by either PRBS-RBD protein nanovaccine (10 μg RBD protein and 50 μg PRBS per each injection) or traditional RBD protein vaccine (10 μg RBD protein per each injection). c The magnitude of RBD-specific T cell response (IFN-γ ELISPOT) induced by either PRBS-RBD protein nanovaccine (10 μg RBD protein and 50 μg PRBS per each injection) or traditional RBD protein vaccine (10 μg RBD protein per each injection). d Using flow cytometry analysis, we assess the secretion of IFN-γ by both CD8+T cells and CD4+T cells in PRBS-RBD protein nanovaccine group (10 μg RBD protein and 50 μg PRBS per each injection) and traditional RBD protein vaccine group (10 μg RBD protein per each injection). e The titer of HIV-specific IgG induced by either PRBS-HIV plasmid nanovaccine (10 μg HIV plasmid and 50 μg PRBS per each injection) or traditional HIV DNA vaccine (10 μg HIV plasmid per each injection). f The magnitude of HIV-specific T cell response (IFN-γ ELISPOT) induced by either PRBS-HIV plasmid nanovaccine (10 μg HIV plasmid and 50 μg PRBS per each injection) or traditional HIV DNA vaccine (10 μg HIV plasmid per each injection). g CD8+ and CD4+ T cells IFN-γ response induced by either PRBS-HIV plasmid nanovaccine (10 μg HIV plasmid and 50 μg PRBS per each injection) or traditional HIV plasmid vaccine (10 μg HIV plasmid per each injection). All values are expressed as mean ± SD. *P < 0.05

Back to article page